|
|
Vol. 27.03 – 02 March, 2026
|
|
|
|
|
|
|
|
|
Scientists reported tripartite motif containing 13 (TRIM13) engineered CAR-macrophages (CAR-Ms) for effectively manipulating the anti-inflammatory phenotype of CAR-Ms, augmenting their anti-fibrosis efficacy. [Nature]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Engineering CAR-NK cells with OR7A10 cDNA enhanced their proliferation, activation, degranulation, cytokine production, death ligand expression, chemokine receptor expression, cytotoxicity, persistence, metabolic fitness, and tumor microenvironment resistance.
[Nature]
|
|
|
|
|
|
Given the unique abilities of macrophages to cross the blood–brain barrier and exert their phagocytic function on tumor cells, researchers genetically engineered macrophages that expressed a CAR targeting mesothelin.
[Nature Biomedical Engineering]
|
|
|
|
|
|
Researchers tested a broad array of strategies to enhance CD4CAR-T cell efficacy, including CRISPR-Cas9-mediated gene editing of immune checkpoint and HIV-associated genes, single and pooled competitive infusions of engineered CAR-T cells, and exogenous antigen boosting.
[Blood]
|
|
|
|
|
|
Scientists developed a PSC-derived induced natural killer lineage-committed progenitor cell therapy (iNKP) in leukemia models. They generated abundant iNKP cells via an organoid culture system.
[Cell Stem Cell]
|
|
|
|
|
|
Investigators developed CAR T cells targeting KRASG12V/HLA-A*02:01 using phage antibody display to identify high-affinity single-chain variable fragments.
[Science Advances]
|
|
|
|
|
|
In natural killer (NK)-competent humanized mice, adoptively transferred, unselected, unmodified NK cells slowed tumor growth in a dose-dependent manner, but NK cells selected to avoid HLA I-driven inhibition were the most competent effectors for PDAC control. [Journal for Immunotherapy of Cancer]
|
|
|
|
|
|
|
|
The authors review the clinical progress of engineered cellular immunotherapies for autoimmunity, focusing on how antigenic target, engineered cell type, CAR design, and treatment regimens affect the therapeutic efficacy and safety of these treatments.
[Nature Biotechnology]
|
|
|
|
|
|
Scientists summarize the mechanisms, epidemiology and management of T cell therapy-associated cytokine release syndrome and subsequent cardiotoxicity. [Nature Reviews Cardiology]
|
|
|
|
|
|
Investigators explore key insights gained from hematologic applications of CAR T cells and T cell engagers, and discuss how these lessons can guide the clinical use of these therapies in autoimmune diseases. [Bone Marrow Transplantation]
|
|
|
|
|
|
|
|
A2 Biotherapeutics, Inc. announced the first patient dosed with A2B543, an autologous CAR T cell therapy, initiating the second arm of the Phase I/II EVEREST-2 study.
[A2 Biotherapeutics, Inc.]
|
|
|
|
|
|
Cellares and the University of Wisconsin School of Medicine and Public Health announced an expansion of their partnership to support clinical production and regulatory advancement of the university’s CRISPR-edited GD2 CAR-T investigational therapy for pediatric and adult solid tumors.
[Cellares (Business Wire, Inc.)]
|
|
|
|
|
|
Researchers at the University of British Columbia and B.C. Children’s Hospital Research Institute have recently discovered how to use stem cells to create the immune cells needed for effective cell therapy. [Canadian Affairs]
|
|
|
|
|
|
|
|
April 15-17, 2026 Newcastle upon Tyne, England, United Kingdom
|
|
|
|
|
|
|
|
|
|
|
St Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
Research Center for Molecular Medicine – Vienna, Austria
|
|
|
|
|
|
|
St. Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
The University of Hong Kong – Hong Kong
|
|
|
|
|
|
|
Vilnius University Life Sciences Center – Vilnius, Lithuania
|
|
|
|
|
|